LAMPERTICO, PIETRO
LAMPERTICO, PIETRO
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti
Noninvasive Assessment of portal Hypertension in Patients With Primary Biliary Cholangitis is Affected by Severity of Cholestasis
2025 V. Calvaruso, C. Celsa, L. Cristoferi, M. Scaravaglio, R. Smith, S. Kaur, G. Di Maria, L. Capodicasa, G. Pennisi, A. Gerussi, E. Nofit, F. Malinverno, P. Lampertico, N. Cazzagon, M. Marzioni, U. Vespasiani-Gentilucci, F. Colapietro, P. Andreone, A.L. De Nalda, C. Rigamonti, M. Viganò, E.G. Giannini, M. Russello, E. Vanni, F. Cerini, A. Orlandini, M. Brunetto, G.A. Niro, G. Vettori, A. Castellaneta, V. Cardinale, D. Alvaro, A. Mega, V.P. Palitti, V. Cossiga, F. Morisco, F. Bellanti, L. Baiocchi, L. Fabris, M. Persico, E. Degasperi, S. Labanca, E. Bonaiuto, F. Pezzato, A. Federico, S. Petta, V. Di Marco, G.F. Mells, E. Culver, P. Invernizzi, C. Cammà, M. Carbone
High Rate of Antibody Response to Multiple Doses of the COVID-19 Vaccine in Liver Transplant Recipients: Analysis of Predictive Factors
2025 N. Zignani, A. Costantino, M. Sagasta, C. Dibenedetto, R. Perbellini, S.C. UCEDA RENTERIA, P. Lampertico, M. Francesca Donato
Comparing methods for plasma HDV RNA quantification in bulevirtide-treated and untreated patients with HDV
2025 M.P. Anolli, S. Uceda Renteria, E. Degasperi, F. Facchetti, D. Sambarino, M. Borghi, R. Perbellini, R. Soffredini, S. Monico, A. Callegaro, P. Lampertico
Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B
2025 M. Buti, J. Heo, Y. Tanaka, P. Andreone, M. Atsukawa, J. Cabezas, E. Chak, C.S. Coffin, K. Fujiwara, N. Gankina, S.C. Gordon, E. Janczewska, A. Komori, P. Lampertico, S. Mcpherson, V. Morozov, R. Plesniak, S. Poulin, P. Ryan, O. Sagalova, G. Sheng, N. Voloshina, Q. Xie, H.J. Yim, S. Dixon, M. Paff, L. Felton, M. Lee, T. Greene, J. Lim, D. Lakshminarayanan, G. Mcgonagle, H. Plein, A.S. Youssef, R. Elston, S. Kendrick, D. Theodore
Patient-reported outcomes in chronic hepatitis delta: An exploratory analysis of the phase III MYR301 trial of bulevirtide
2025 M. Buti, H. Wedemeyer, S. Aleman, V. Chulanov, V. Morozov, O. Sagalova, T. Stepanova, R.G. Gish, A. Lloyd, A.M. Kaushik, V. Suri, D. Manuilov, A.O. Osinusi, J.F. Flaherty, P. Lampertico
Reappraisal of the conventional hemostasis tests as predictors of perioperative bleeding in the era of rebalanced hemostasis in cirrhosis
2024 A. Tripodi, M. Primignani, R. D'Ambrosio, G. Tosetti, V. La Mura, P. Lampertico, F. Peyvandi
Modelling HDV kinetics under the entry inhibitor bulevirtide suggests the existence of two HDV-infected cell populations
2024 L. Shekhtman, S.J. Cotler, E. Degasperi, M.P. Anolli, S.C. Uceda Renteria, D. Sambarino, M. Borghi, R. Perbellini, F. Facchetti, F. Ceriotti, P. Lampertico, H. Dahari
Comprehensive investigation of platelet function in patients with cirrhosis
2024 A. Lecchi, G. Tosetti, C. Ghali, S. La Marca, M. Clerici, L. Padovan, E.A. Femia, M. Primignani, V. La Mura, P. Lampertico, F. Peyvandi, A. Tripodi
Safety of Sofosbuvir-Based Direct-Acting Antivirals for Hepatitis C Virus Infection and Direct Oral Anticoagulant Co-Administration
2024 V. Rosato, R. Nevola, M. Dallio, P. Di Micco, A. Spinetti, L. Zeneli, A. Ciancio, M. Milella, P. Colombatto, G. D'Adamo, E. Rosselli Del Turco, P. Gallo, A. Falcomatà, S. De Nicola, N. Pugliese, R. D'Ambrosio, A. Soria, E. Colella, A. Federico, M. Brunetto, U. Vespasiani-Gentilucci, A. Aghemo, P. Lampertico, A. Izzi, D. Mastrocinque, E. Claar
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure
2024 C. Graf, R. D'Ambrosio, E. Degasperi, S. Paolucci, J. Llaneras, J. Vermehren, G. Dultz, K. Peiffer, F. Finkelmeier, E. Herrmann, S. Zeuzem, M. Buti, P. Lampertico, J. Dietz, C. Sarrazin
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories
2024 D. Razavi-Shearer, H. Child, K. Razavi-Shearer, A. Voeller, H. Razavi, M. Buti, F. Tacke, N. Terrault, S. Zeuzem, Z. Abbas, A. Aghemo, U.S. Akarca, N. Al Masri, A. Alalwan, M.A. Blome, A. Jerkeman, S. Aleman, H. Kamal, A. Alghamdi, M. Alghamdi, S. Alghamdi, W. Al-Hamoudi, E. Ali, A. Aljumah, I. Altraif, J. Amarsanaa, T. Asselah, O. Baatarkhuu, A. Babameto, Z. Ben-Ari, T. Berg, M. Biondi, W. Braga, C. Brandao-Mello, R. Brown, M. Brunetto, J. Cabezas, M. Cardoso, A. Martins, H.L.Y. Chan, H. Cheinquer, C.-. Chen, H.-. Yang, P.-. Chen, C.-. Chien, W.-. Chuang, L.C. Garza, B. Coco, C. Coffin, N. Coppola, M. Cornberg, A. Craxi, J. Crespo, L. Cuko, V. De Ledinghen, A.-. Duberg, O. Etzion, M.L. Ferraz, P. Ferreira, X. Forns, G. Foster, J. Fung, G. Gaeta, J. Garcia-Samaniego, J. Genov, L. Gheorghe, P. Gholam, R. Gish, J. Glenn, S. Hamid, J. Hercun, Y.-. Hsu, C.-. Hu, J.-. Huang, R. Idilman, W. Jafri, N. Janjua, D. Jelev, J. Jia, M. Kaberg, K. Kaita, J.-. Kao, A. Khan, D.Y. Kim, L. Kondili, M. Lagging, P. Lampertico, P. Lazaro, J.V. Lazarus, M.-. Lee, Y.-. Lim, C. Lobato, G. Macedo, R. Marinho, P. Marotta, M.C. Mendes-Correa, N. Mendez-Sanchez, M.-. Navas, Q. Ning, N. Ormeci, M. Orrego, C. Osiowy, C. Pan, M. Pessoa, Z. Piracha, C. Pop, H. Qureshi, G. Raimondo, A. Ramji, S. Ribeiro, C. Rios-Hincapie, M. Rodriguez, W. Rosenberg, D. Roulot, S. Ryder, U. Saeed, R. Safadi, D. Shouval, F. Sanai, J.F. Sanchez-Avila, T. Santantonio, C. Sarrazin, W.-. Seto, M. Simonova, J. Tanaka, T. Tergast, O. Tsendsuren, C. Valente, J.M. Villalobos-Salcedo, Y. Waheed, G. Wong, V. Wong, T. Yip, J.-. Wu, M.-. Yu, M.-. Yuen, C. Yurdaydin, E. Zuckerman
Differential HBV RNA and HBcrAg patterns in untreated patients with chronic hepatitis delta
2024 E. Degasperi, C. Scholtes, B. Testoni, S.U. Renteria, M.P. Anolli, C. Charre, F. Facchetti, M. Plissonnier, D. Sambarino, R. Perbellini, S. Monico, A. Callegaro, E. García-Pras, S. Lens, M.F. Cortese, X. Forns, S. Pérez-Del-Pulgar, M. Heil, M. Levrero, F. Zoulim, P. Lampertico
HCC risk in patients who are HBeAg-positive and have chronic hepatitis B under long-term nucleos(t)ide analogue therapy: New insights from Asia
2024 G. Papatherodoridis, P. Lampertico
Prevalence of HCV infection in Europe in the DAA era: Review
2024 R. D'Ambrosio, M.P. Anolli, N. Pugliese, C. Masetti, A. Aghemo, P. Lampertico
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis—A real-world case series
2024 C. Dietz-Fricke, E. Degasperi, M. Jachs, B. Maasoumy, F.P. Reiter, A. Geier, J.M. Grottenthaler, C.P. Berg, K. Sprinzl, S. Zeuzem, J. Gödiker, B. Schlevogt, T. Herta, J. Wiegand, R. Soffredini, H. Wedemeyer, K. Deterding, T. Reiberger, P. Lampertico
Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study
2024 H.L.A. Janssen, Y. Lim, P. Lampertico, J. Heo, C. Chen, C. Fournier, T.Y.O. Tsang, H. Bae, C. Chen, C.S. Coffin, S.H. Ahn, H. Trinh, J.F. Flaherty, F. Abramov, Y. Zhao, Y. Liu, A. Lau, P. German, W. Chuang, K. Agarwal, E. Gane
Liver stiffness measurement as a noninvasive method for the diagnosis of liver cirrhosis in patients with chronic hepatitis D virus infection
2024 L. Sandmann, E. Degasperi, K. Port, S. Aleman, J.J. Wallin, D. Manuilov, B.L. Da, M. Cornberg, P. Lampertico, B. Maasoumy, H. Wedemeyer, K. Deterding
Sodium taurocholate cotransporting polypeptide (NTCP) polymorphisms may influence HDV RNA load and early response to bulevirtide
2024 P. Toniutto, E. Falleti, S. Cmet, A. Cussigh, E. Degasperi, M.P. Anolli, D. Sambarino, F. Facchetti, M. Borghi, R. Perbellini, S. Monico, P. Lampertico
Antiviral therapy for chronic hepatitis delta: new insights from clinical trials and real-life studies
2024 P. Lampertico, M.P. Anolli, D. Roulot, H. Wedemeyer
Reply to: Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies
2024 M.G. Ghany, M. Buti, P. Lampertico, H.M. Lee